VION Sells Banner Pharmacaps to Patheon Inc.
The sales price is U.S. $255 million. VION announced the definitive agreement to sell Banner Pharmacaps to Patheon Inc. on 29 October 2012. The sale is the result of VION’s revised strategy which was announced on 15 June 2012 and involves the accelerated, vigorous implementation of various measures and investments.
18 Dec 2012 --- VION N.V. has closed the sales of its company Banner Pharmacaps on 14 December 2012 to Canadian company Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry.
The sales price is U.S. $255 million. VION announced the definitive agreement to sell Banner Pharmacaps to Patheon Inc. on 29 October 2012. The sale is the result of VION’s revised strategy which was announced on 15 June 2012 and involves the accelerated, vigorous implementation of various measures and investments. VION companies that are no longer part of the company’s core activities will be disinvested. Banner Pharmacaps, a specialty developer and manufacturer of value added proprietary softgel capsules for the pharmaceutical industry, occupied an independent position within VION.
VION N.V. is an internationally operating food company with two core activities: Food and Ingredients. The group produces high-quality foodstuffs for humans and animals. In 2011, VION's turnover amounted to €9.5 billion. At the close of 2012, the company employed well over 25,000 staff. VION is not a listed company and has one shareholder, the Dutch Zuidelijke Land- en Tuinbouworganisatie (ZLTO), an agricultural and horticultural association with some 18,000 members. VION’s head office is located in Eindhoven, the Netherlands.
Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of solid and sterile dosage forms.
The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. The company's integrated development and manufacturing network of nine manufacturing facilities and nine development centers across North America and Europe, enables customer products to be launched with confidence anywhere in the world.
